Clinical trials: Hepatic Malignancies
Liver Cirrhosis, Hepatoma
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol
New strategy to improve the outcomes in patients with HCC and acute variceal bleeding. NSBB added to endoscopic ligation may further reduce rebleeding in cirrhotic patients.
- Trial name
- NCT01298284
- Testing
- propranolol
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Colorectal Cancer, Neoplasm Metastasis
CCR5-blockade in Metastatic Colorectal Cancer
The surface molecule CCR5 is found on tumor cells within liver metastases of colorectal cancer. Inhibition of this molecule leads to a reduction in growth signals for tumor cells and subsequent slowed or halted tumor growth.
- Conditions
- Colorectal Cancer, Neoplasm Metastasis, Liver Metastases
- Trial name
- MARACON (NCT01736813)
- Testing
- Maraviroc
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Colorectal Cancer
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in combination with intravenous cetuximab versus intravenous irinotecan in combination with intravenous cetuximab in the treatment of patients…
- Trial name
- DEBIRITUX (NCT01060423)
- Testing
- Cetuximab, Irinotecan, Irinotecan eluting BEADS
- Where
- 13 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Hans-Joachim Schmoll, MD
Hepatocellular Carcinoma, Liver Cancer
Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE
The purpose of the study is to find out if a study agent called Lumason® microbubbles may be helpful for people with lesions in the liver.
- Trial name
- NCT04150874
- Testing
- Lumason®
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Arteriovenous Malformation, Hemangioma
Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB
This is an open-label whole-body PET/CT study for investigation of radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and diagnostic performance of 68Ga-NEB in healthy volunteers and patients with suspected…
- Conditions
- Arteriovenous Malformation, Hemangioma, Neoplasms Lymph Nodes, Lymphedema
- Trial name
- NCT02496013
- Testing
- 68Ga-NEB
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Cirrhosis, HCC - Hepatocellular Carcinoma
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
- Conditions
- Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis
- Trial name
- NCT07132515
- Testing
- Enoxaparin, warfarrin, or apixaban
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Hepatocellular Carcinoma
The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus
This study uses to suppress the growth of tumors, extend the patient's survival time and improve the quality of life as much as possible.
- Trial name
- NCT03520257
- Testing
- Apatinib, Radiotherapy
- Volunteers
- 50 people
- Sponsor
- Guangxi Medical University
Liver Metastasis, Colorectal Cancer
Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)
Despite the advances in the medical treatment of unresectable liver metastases from colorectal cancer there is currently no curative treatment option available for these patients.
- Trial name
- DECIT (NCT02316028)
- Testing
- Decitabine
- Where
- 2 sites in Belgium
- Volunteers
- 11 people
- Sponsor
- Universitair Ziekenhuis Brussel
HCC, Hepatocellular Carcinoma
Y-90 Treatment Response Using Transarterial Radioembolization
This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE).
- Conditions
- HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm
- Trial name
- TARE (NCT07145801)
- Testing
- Lumason, Sonazoid
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Jefferson University
Carcinoma. Hepatocellular
Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis
The presence of portal vein tumor thrombosis (PVTT)in patients with HCC is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT01911000
- Testing
- RT and hyperthermia after TACE
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Trial of TG4023 Combined With Flucytosine in Liver Tumors
This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary…
- Trial name
- NCT00978107
- Testing
- MVA-FCU1, flucytosine
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- Transgene
Liver Cancer
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
To learn if using the TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres…
- Trial name
- NCT05743842
- Testing
- TriSalus™ TriNav™Infusion System, Angiogram, Y90-radioembolization procedure
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatic Carcinoma, Hepatic Metastasis
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
The goal of this double-blind clinical trial is to compare the efficacy of octreotide versus placebo in laparoscopic hepatectomy surgery in patients diagnosed with resectable hepatocarcinoma or liver metastases.
- Trial name
- NCT06085976
- Testing
- Octreotide
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Hepatocellular Carcinoma With Major Portal Vein Thrombosis
Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
This is a randomized, double-blinded, controlled, phase II study. The purpose is to evaluate efficacy and safety of the combination therapy of HAIC (Hepatic arterial infusion chemotherapy) with HLX10 (PD-1 antibody) and HLX04…
- Trial name
- NCT04947826
- Testing
- HAIC (Hepatic arterial infusion chemotherapy), HLX10 (PD-1 antibody), HLX04 (VEGF antibody)
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Study of Automatic Image Fusion of a CT Volume With Ultrasound During Percutaneous Ablation Treatment of Hepatic Tumors
The automatic fusion of the ultrasound with a cone-beam CT volume will guide the positioning of the electrodes, despite the visibility of the tumor in ultrasound, in patients treated with irreversible electroporation in the…
- Trial name
- IAT (NCT04420026)
- Testing
- Interact Active Tracker
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Failure, Carcinoma, Hepatocellular
Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study
This study will assess the feasibility of lower limb-ischemia induced Remote Ischemic Conditioning (RIC) in the perioperative period before, during, and after Orthotopic Liver Transplantation (OLT).
- Trial name
- NCT02635347
- Testing
- Remote Ischemic Conditioning (RIC), Pneumatic tourniquet
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Rutgers, The State University of New Jersey
Moderate Hepatic Impairment
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
The pharmacokinetics of a single dose of pexidartinib was investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.
- Trial name
- NCT04223635
- Testing
- Pexidartinib
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Ovarian Neoplasms, Neoplasms
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
Niraparib (Zejula®)is extensively metabolized and eliminated primarily by hepatic and renal pathways. The purpose of this study is to evaluate pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment…
- Conditions
- Ovarian Neoplasms, Neoplasms, Solid Tumor, Hepatic Impairment
- Trial name
- NCT03359850
- Testing
- Niraparib
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Tesaro, Inc.
Hepatocellular Carcinoma
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Hepatic artery infusion chemotherapy (HAIC) and anti-programmed cell death protein-1ligand (PD-L1) immunotherapy have shown promising outcomes in patients with advanced hepatocellular carcinoma (HCC), respectively.
- Trial name
- NCT04945720
- Testing
- Hepatic artery infusion chemotherapy（HAIC）, Durvalumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
Hepatic artery infusion chemotherapy (HAIC) is a locoregional therapy commonly used in hepatocellular carcinoma (HCC), with high response rates and minimal impairment of liver function reported.
- Trial name
- NCT06632717
- Testing
- Cisplatin, 5-fluorouracil, Lipiodol embolization
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- National Taiwan University Hospital